Imagine being born unable to hear a single sound — and then, after a single infusion into the cochlea, beginning to hear your parents' voices for the first time. That's no longer a future possibility or an experiment. As of April 2026, it's an FDA-approved medical treatment.

A gene therapy targeting something called the OTOF gene has become the most talked-about development in hearing medicine in decades. In October 2025, results from the CHORD clinical trial were published in the New England Journal of Medicine — one of the most prestigious medical journals in the world — covering 12 children. Nine of them reached the study's main hearing target at 24 weeks, and Regeneron counts 11 of the 12 as having clinically meaningful improvement, including 3 with normal hearing. About six months later, on April 23, 2026, the FDA granted accelerated approval to that therapy.

If you're a parent of a child with hearing loss, or if you simply follow hearing health news, you've probably seen the headlines. But the coverage has mostly been written for medical professionals or has skipped over the practical questions families actually have. This post is my attempt to fill that gap.

The Headline: It's Approved

On April 23, 2026, the FDA granted accelerated approval to Otarmeni (lunsotogene parvec-cwha) — developed under the name DB-OTO — making it the first gene therapy approved for genetic hearing loss (Regeneron calls it the first gene therapy to restore a neurosensory function to normal levels). It's approved for children and adults with severe-to-profound or profound hearing loss from two confirmed OTOF variants, preserved outer hair cell function, and no cochlear implant in that ear. Regeneron says it will provide the therapy at no cost to clinically eligible people in the U.S. It also says that may not cover the out-of-pocket cost of administering it, so ask your care team and your insurer.

A newborn baby asleep on a blanket
Photo: Pexels.

First: What Is the OTOF Gene, and Why Does It Matter?

OTOF stands for otoferlin, a protein that plays a critical role in how your inner ear converts sound into electrical signals that the brain can understand. Think of the inner ear like a recording studio. The tiny hair cells inside the cochlea are the microphones that pick up sound. Otoferlin is the cable that connects those microphones to the mixing board — without it, the signal never gets through.

Children born with mutations in both copies of the OTOF gene (one inherited from each parent) produce little or no otoferlin. Their inner ear structures are physically intact — the microphones are there — but the connection is broken. The result is profound deafness from birth, called DFNB9 or OTOF-related hearing loss.

This is sometimes called auditory neuropathy spectrum disorder, or ANSD. It shows up in a distinctive way on hearing tests: the outer hair cells are often still working (so an OAE screening can look normal at first), but the ABR — which measures the nerve signal — shows no response. This pattern is an important clue that OTOF should be suspected.

How Common Is OTOF Hearing Loss?

Regeneron puts OTOF hearing loss at 20 to 50 babies born in the United States each year (its April 2026 release says about 50). Estimates of its share of inherited hearing loss present at birth run from about 1% to 8%, depending on the study. It's rare — but for families affected, it's everything.

What Is the Gene Therapy and How Does It Work?

The treatment works by delivering a working copy of the OTOF gene directly into the cochlea through a tiny injection. The gene is carried inside a modified, harmless virus called an adeno-associated virus (AAV), which acts like a molecular delivery truck — getting the genetic instructions into the inner hair cells without altering the rest of the child's DNA.

Once inside, the hair cells begin producing otoferlin. The broken connection between the ear and the brain gets restored. And the brain — which has never processed sound before — begins learning to interpret the signals it's suddenly receiving.

The now-approved therapy, Otarmeni (developed as DB-OTO by Regeneron Pharmaceuticals), uses a dual-AAV approach to deliver the full OTOF gene, which is too large for a single virus to carry. It uses a specialized promoter called Myo15 to target the gene specifically to the inner hair cells, and it's delivered through a single intracochlear infusion using a surgical approach similar to cochlear implantation.

11/12
Of 12 children in the NEJM report, clinically meaningful improvement (Regeneron's count)
3/12
Achieved completely normal hearing levels
2026
Year the first OTOF gene therapy won FDA approval

Gene Therapy vs. Cochlear Implants: The Question Every Parent Is Asking

This is where things get genuinely complicated — and where the stakes are highest for families making decisions in real time.

Cochlear implants have been around for decades and have given hundreds of thousands of children access to sound. They work by bypassing the damaged inner ear entirely and directly stimulating the auditory nerve with electrical signals. They are proven, safe, and highly effective — particularly when implanted early in life.

Gene therapy, by contrast, aims to restore biological hearing — the natural kind, using the ear's own structures. The early results suggest it can produce a quality of hearing that cochlear implants can't fully replicate, including better performance in noisy environments and more natural sound perception.

But here's the critical detail every family needs to understand: a cochlear implant in an ear typically disqualifies that ear from gene therapy. The approved therapy specifically requires no prior cochlear implant in the ear being treated, and the surgical changes to the cochlea affect eligibility. This means the sequence of decisions — which treatment, in which ear, and when — has lasting consequences.

"The question isn't which treatment is better. It's which treatment is right for this child, in this ear, at this moment — and what stays possible if you choose one path."
Factor Cochlear Implant OTOF Gene Therapy (Otarmeni)
Availability Widely available FDA-approved (Apr 2026)
Who it's for Most causes of severe-to-profound loss Only OTOF/otoferlin-related loss
Hearing quality Good, electrical signal Potentially natural/normal
Noisy environments Challenging Early results more promising
Reversible? No (affects gene therapy eligibility) Not yet known long-term
Age range treated Earlier is generally better Pediatric and adult patients (trial participants were 10 months to 16 years)
Requires device Yes, external processor worn daily No external device after treatment
Evidence base Decades of outcomes data Accelerated approval; follow-up in the published data ran up to about 72 weeks

Why Timing Still Matters Enormously

One of the most important things I've learned following this space is that the urgency around early intervention hasn't gone away — even now that gene therapy is approved. The developing brain has a critical window during which it learns to process sound. Miss that window, and language development suffers, regardless of which technology eventually provides the hearing.

Children who get a cochlear implant earlier tend to do better with language. The same principle of neuroplasticity applies to gene therapy — the brain benefits most when it receives sound signals during the critical early period of development. The trial enrolled children as young as 10 months.

This creates a genuinely difficult dilemma for families whose children are identified with OTOF mutations early. The emerging approach at leading centers is to weigh cochlear implantation in one ear to provide immediate auditory access while preserving gene therapy eligibility in the other — though now that the therapy is approved, more families may be candidates for gene therapy directly, depending on timing and their care team's assessment.

What Families Should Ask Their Care Team

If your child has been diagnosed with profound congenital hearing loss, ask specifically about genetic testing for OTOF. Ask whether your center has access to the approved gene therapy and a protocol for evaluating eligibility alongside cochlear implant planning. And ask about ear selection — the decision of which ear receives which intervention has lasting implications.

What the Research Actually Shows Right Now

The CHORD trial results published in the New England Journal of Medicine in October 2025 are the published evidence behind the approval, but the FDA's decision rests on the wider CHORD trial: 24 children aged 10 months to 16 years were treated, 20 could be evaluated for effectiveness, and the FDA says 80% of those had improved hearing. Children received a single dose per ear, infused into the cochlea. In the NEJM paper, the primary goal was reaching a hearing threshold of 70 dB or better at 24 weeks — a level that generally avoids the need for cochlear implantation.

11 of 12 treated participants achieved clinically meaningful improvement (the trial's primary endpoint was met with 9 participants reaching the 70 dB threshold). Three achieved normal hearing. And importantly, improvements continued to develop and remained stable over months of follow-up — meaning the auditory brain was still learning to process the new signals well after the treatment itself.

The approval was an accelerated approval, which means the FDA cleared the therapy based on this early evidence and continued approval may depend on showing the hearing improvement lasts and that it helps speech development and quality of life. It was the first gene therapy approved under the FDA's National Priority Voucher program, and the FDA approved it 61 days after the application was filed.

Otarmeni isn't the only OTOF program either. Other gene therapies are still in clinical trials, including Eli Lilly/Akouos's AK-OTOF (Lilly reported in 2024 that the first participant, an 11-year-old, regained hearing within 30 days) and Sensorion's SENS-501. The field is moving fast, and the research is also paving the way toward therapies for other genetic causes of hearing loss.

What This Doesn't Mean (Yet)

I want to be careful here, because I've seen some coverage that gets ahead of the evidence. Even with approval, OTOF gene therapy is not a universal cure. It treats one specific genetic cause. The approval was accelerated and based on follow-up measured in months, not decades (up to about 72 weeks for some children in the published data) — so we don't yet know how durable the results are over a lifetime, or whether boosters will ever be needed. The FDA lists middle ear infection, nausea, dizziness and procedural pain as common side effects, and says the therapy isn't recommended for people whose inner-ear anatomy prevents safe access. Access is still limited, so ask your care team where it's offered.

OTOF mutations also represent a small fraction of all hearing loss — somewhere between 1% and 8% of inherited hearing loss present at birth, depending on the study. The vast majority of children with hearing loss have different causes, and this therapy won't help them directly (though the research is paving the way for therapies targeting other genes).

None of this diminishes what's been achieved. It just means families should approach this with realistic expectations and work closely with specialized centers experienced in OTOF diagnosis and treatment.

Frequently Asked Questions

How do I know if my child might have an OTOF mutation?
The key clue is an auditory neuropathy pattern on hearing testing — present OAEs (outer hair cells working) but absent or abnormal ABR. If your child was diagnosed with ANSD or auditory neuropathy, specifically ask your audiologist or ENT about genetic testing for OTOF mutations. Comprehensive genetic hearing panels are increasingly standard and can confirm the diagnosis — and confirming biallelic OTOF variants is now a requirement for accessing the approved therapy.
If my child already has a cochlear implant, is gene therapy still an option?
It depends on the ear. The approved therapy requires no prior cochlear implant in the ear being treated. If your child has a cochlear implant in one ear, the other ear may still be a candidate — which is why ear selection has become such an important early conversation at specialized centers.
How do we access the approved gene therapy?
Otarmeni is delivered at specialized centers experienced in cochlear surgery. Some academic centers, such as Children's Hospital of Philadelphia (CHOP), list gene therapy for genetic hearing loss on their own sites. Eligibility requires molecularly confirmed biallelic OTOF mutations, severe-to-profound or profound hearing loss, preserved outer hair cell function, and no prior cochlear implant in the ear to be treated. Ask your ENT or audiologist for a referral to a center that offers it.
Will insurance cover this?
Regeneron has announced it will provide Otarmeni itself at no cost to clinically eligible patients in the U.S. That said, the surgical procedure, anesthesia, and related care are separate, and those out-of-pocket costs may vary by site and insurer. If your family is pursuing treatment, ask the center directly about what the therapy covers versus what's billed through your insurance.
What about hearing aids — are they useful for OTOF hearing loss?
Often only a little. OTOF hearing loss is an auditory neuropathy: the inner ear works, but the signal doesn't get passed on to the hearing nerve properly, so making sound louder doesn't fix it. That is one reason cochlear implants have been the main treatment, and why gene therapy, which targets the cause, is so significant. Ask your audiologist what is right for your child.

Stay Updated on Hearing Health Research

I cover the hearing aid and hearing health space as someone who lives it every day. If you want plain-language updates on developments like this one, join my email list. You'll get my free guide, 5 Questions to Ask Before You Buy a Hearing Aid, first.

The Bottom Line

OTOF gene therapy is the most significant development in hearing medicine in a generation — and as of April 2026, it's no longer experimental. For the small number of children and adults whose deafness is caused by OTOF mutations, there is now an FDA-approved path to natural hearing that didn't exist even two years ago.

For families navigating this right now, the most important things are: get comprehensive genetic testing early, find a center experienced in both cochlear implants and gene therapy, have the ear selection conversation before any intervention, and don't let the timeline of any one treatment delay the early auditory access that language development requires.

The science is moving fast. The families who will benefit most are the ones who understand what's available now, what's still in trials, and what decisions preserve the most options.

As always — I'm not a doctor, and nothing here is medical advice. But I'll keep translating the research as clearly as I can, because families navigating hearing loss deserve information in plain English.

Sources & References

Medical and regulatory facts on this page come from these sources, read on the dates shown. This page is not medical advice; talk to a pediatric audiologist or ENT.

  1. U.S. Food and Drug Administration. FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program (April 23, 2026: indication, accelerated approval, 24 children treated and 20 evaluable with 80% improved hearing, common side effects, approval 61 days after filing; checked October 24, 2026). fda.gov
  2. U.S. Food and Drug Administration. OTARMENI (product page: indication, preserved outer hair cell function, no prior cochlear implant in the same ear; checked October 24, 2026). fda.gov
  3. Regeneron. Otarmeni Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. (April 23, 2026: free in the U.S., administration costs outside Regeneron’s control, about 50 U.S. newborns a year; checked October 24, 2026). investor.regeneron.com
  4. DB-OTO Gene Therapy for Inherited Deafness. New England Journal of Medicine (12 children; 9 of 12 met the primary endpoint of 70 dB HL or better at week 24; 3 had average normal hearing sensitivity; checked October 24, 2026). nejm.org
  5. Regeneron. DB-OTO Results in the New England Journal of Medicine (October 12, 2025: 11 of 12 with clinically meaningful improvement, ages 10 months to 16 years, 20 to 50 U.S. newborns a year; checked October 24, 2026). investor.regeneron.com
  6. ENT Today. From Genes to Hearing: What Otolaryngologists Need to Know About Gene Therapy for Hearing Loss (OTOF hearing loss as auditory neuropathy with normal OAEs and absent or abnormal ABR; otoferlin-mediated auditory neuropathy in 1 to 8% of patients; checked October 24, 2026). enttoday.org
  7. Eli Lilly. Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss (AK-OTOF: first participant, 11 years old, restored hearing within 30 days; checked October 24, 2026). investor.lilly.com
  8. Children’s Hospital of Philadelphia. Gene Therapy for Genetic Hearing Loss (an example of a center that lists the treatment; checked October 24, 2026). chop.edu